| Company Name: |
Wuhan Topule |
| Tel: |
+86-02787215551 19945035818 |
| Email: |
2936752263@qq.com |
|
| | GLP-1 receptor agonist 5 Basic information |
| Product Name: | GLP-1 receptor agonist 5 | | Synonyms: | GLP-1 receptor agonist 5;TT-OAD2 free base;L-Phenylalanine, N-[[(3S,8S)-3-[4-[(3,4-dichlorophenyl)methoxy]phenyl]-2,3,6,7,8,9-hexahydro-7-[(1S)-1-phenylpropyl]-1,4-dioxino[2,3-g]isoquinolin-8-yl]carbonyl]-4-(2,3-dimethyl-4-pyridinyl)-;(S)-2-{[(3S,8S)-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-7-((S)-1-phenyl-propyl)-2,3,6,7,8,9-hexahydro-[1,4]dioxino[2,3-g]isoquinoline-8-carbonyl]-amino} | | CAS: | 1246826-07-2 | | MF: | C50H47Cl2N3O6 | | MW: | 856.83 | | EINECS: | | | Product Categories: | | | Mol File: | 1246826-07-2.mol |  |
| | GLP-1 receptor agonist 5 Chemical Properties |
| | GLP-1 receptor agonist 5 Usage And Synthesis |
| Uses | TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 free base has the potential for diabetes treatment[1][2]. | | in vivo | TT-OAD2 (3 mg/kg; intravenous injection; male human GLP-1 receptor knock-in and knockout mice) treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice[1]. | Animal Model: | Male human GLP-1 receptor knock-in and knockout mice (6-11 months of age) with intravenous glucose tolerance tests[1] | | Dosage: | 3 mg/kg | | Administration: | Intravenous injection (Single dose) | | Result: | Induced plasma insulin.
|
| | References | [1] Zhao P, et al. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature. 2020 Jan;577(7790):432-436. DOI:10.1038/s41586-019-1902-z
[2] Transtech Pharma, et al. Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof. WO2010114824A1. |
| | GLP-1 receptor agonist 5 Preparation Products And Raw materials |
|